Agios Pharmaceuticals (FRA:8AP) 3-Year EBITDA Growth Rate : -13.50% (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals 3-Year EBITDA Growth Rate?

Agios Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2024 was €-1.48.

During the past 3 years, the average EBITDA Per Share Growth Rate was -13.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -5.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -12.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Agios Pharmaceuticals was 11.20% per year. The lowest was -62.70% per year. And the median was -18.85% per year.

Competitive Comparison of Agios Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Agios Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agios Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

Agios Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Agios Pharmaceuticals (FRA:8AP) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Agios Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Agios Pharmaceuticals (FRA:8AP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (FRA:8AP) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

AGIO:USA AGIO:Mexico 8AP:Germany

Address

88 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.agios.com

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Agios Pharmaceuticals (FRA:8AP) Headlines

No Headlines